-
TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade
Saturday, June 2, 2018 - 4:16pm | 477Read More...TapImmune, Inc. (NASDAQ: TPIV) will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note. The Analyst WBB Securities analyst Steve Brozak upgraded TapImmune from a Speculative Buy...
-
Could ViroPharma Benefit from Multiple Generic Versions of VANCOCIN?
Wednesday, April 11, 2012 - 12:28pm | 374Read More...Yesterday morning, the US Food and Drug Administration approved three drug manufacturers' generic versions of ViroPharma's (NASDAQ: VPHM) VANCOCIN HCl capsules. According to Watson Pharmaceuticals' (NYSE: WPI) statment, VANCOCIN is indicated for the treatment of C. difficile-associated diarrhea and...
-
WBB Securities Upgrades NeoStem to Buy
Thursday, January 19, 2012 - 9:55am | 26Read More...WBB Securities has upgraded NeoStem (NYSE: NBS) from Speculative Buy to Buy and has established a $2 price target.
-
WBB Securities Upgrades ViroPharma to Strong Buy
Thursday, December 15, 2011 - 8:44am | 25Read More...WBB Securities has upgraded ViroPharma (NASDAQ: VPHM) to Strong Buy and has raised the price target to $31.25.
-
Hearing Affymax Upgraded to Strong Buy at WBB Securities
Tuesday, September 27, 2011 - 7:23amRead More... -
WBB Securities Upgrades Cyberonics To Strong Buy, $38 PT
Friday, June 3, 2011 - 7:25am | 15Read More...WBB Securities has upgraded Cyberonics (NASDQ: CYBX) to Strong Buy and maintains its $38 price target.
-
Cantel Medical Downgraded to Sell at WBB Securities
Wednesday, November 24, 2010 - 11:27am | 28Read More...Cantel Medical (NYSE: CMN) is downgraded from Hold to Sell at WBB Securities. The price target is raised from $15 to $16.25.
-
More Pip For PIP (PIP)
Monday, October 18, 2010 - 9:33am | 64Read More...Shares of PharmAthene, Inc. (NYSE: PIP) are continuing their run higher, gaining another 18% today, as shares continue their march higher from last week. This morning, WBB Securities put a $6 price target on shares. PharmAthene, Inc., a biodefense company, engages in the development and...
